VFA
VKTX icon

Valeo Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Valeo Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-710
Closed -$4K – 1784
2021
Q1 		$4K Hold
710
– – ﹤0.01% 1651
2020
Q4 		$4K Buy
+710
New +$4.3K ﹤0.01% 1433

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Valeo Financial Advisors's VKTX Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 710 shares — an estimated $4K sold.

Valeo Financial Advisors first reported a position in VKTX in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 710 Viking Therapeutics shares in Q2 2021, an estimated $4K.
  • Valeo Financial Advisors first reported a position in Viking Therapeutics in Q4 2020 and held it in 2 quarters.
  • Valeo Financial Advisors's Viking Therapeutics position peaked at $4K in Q1 2021.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.